Table 1.
Patient characteristics
| All patients (n = 182) | |
|---|---|
| Demographic parameters | |
| Age, years, mean (SD) | 54.2 (11.8) |
| Female sex, n (%) | 135 (75) |
| Disease parameters | |
| Disease duration in years, mean (SD) | 9.7 (10.3) |
| DAS28, mean (SD) | 5.1 (1.2) |
| Erosive disease, n (%) | 131 (72) |
| Nodules, n (%)a | 43 (24) |
| Laboratory parameters | |
| ESR, mm/h, mean (SD) | 24.5 (18.0) |
| CRP, mg/L, mean (SD) | 17.8 (22.1) |
| IgM-RF titer, IU/ml, mean (SD)b | 124.7 (279) |
| IgM-RF-positive, n (%)b | 95 (59) |
| ACPA titer, AU/ml, mean (SD)c | 1563 (2680) |
| ACPA-positive, n (%)c | 131 (75) |
| IFN score, mean (SD) | 0.26 (1.01) |
| Medication parameters | |
| MTX use, n (%) | 152 (84) |
| MTX dosage in mg/week, mean (SD) | 21.0 (6.3) |
| Prednisone use, n (%) | 52 (29) |
| Prednisone dosage in mg/day, mean (SD) | 7.2 (3.5) |
| HCQ use, n (%) | 35 (19) |
| SSZ use, n (%) | 27 (15) |
Abbreviations: ACPA Anticitrullinated protein antibodies, CRP C-reactive protein, DAS28 28-joint Disease Activity Score, ESR Erythrocyte sedimentation rate, HCQ Hydroxychloroquine, IFN Interferon IgM-RF Immunoglobulin M rheumatoid factor, MTX Methotrexate, SSZ Sulfasalazine
aNot available for 6 patients
bNot available for 21 patients
cNot available for 7 patients